Developing Novel Selective Modulators of Mitochondrial Dynamics (SeMMiDs)A differentiated therapeutic approach for treating aggressive cancer Raleigh, NC. January 9th, 2023 – Bantam Pharmaceutical, LLC announces that it is presenting at the Biotech Showcase taking place in San Francisco, the 9th-11th of January and virtually, on demand the 18th and 19th of January. Bantam Pharmaceutical is […]
RESEARCH TRIANGLE PARK, N.C., June 23, 2022 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, announced that new data on the mechanism of action of its lead clinical candidate BTM-3566 will be presented at the Third AACR International Meeting - Advances in Malignant Lymphoma taking place on the 23-26 […]
RESEARCH TRIANGLE PARK, N.C., April 8th, 2022 - Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, will present new data on its lead drug candidate BTM-3566 at AACR 2022 taking place the 8th-13th of April in New Orleans. The data demonstrate that BTM-3566 co-opts a specific mitochondrial quality control […]
BTM-3566 demonstrated robust therapeutic responses in Diffuse Large B-Cell Lymphoma models, both in vitro and in vivo RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2021 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, announced that data on the activity and mechanism of BTM-3566, a novel, first-in-class oral compound […]
Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology Oral Presentation Will Focus on InVitro and InVivo Responses to BTM-3566 in Diffuse Large B-Cell Lymphoma RESEARCH TRIANGLE PARK, N.C., November 18, 2021 -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics […]
Bantam Pharmaceutical Completes $25 Million Seed Funding to Finalize Preclinical Development and Prepare for First in Humans Trials IND Application Expected in Early 2022 for Its Lead Product BTM-3566 Company Establishes Operations in the Research Triangle Park NEWS PROVIDED BY Bantam Pharmaceutical, LLC Sep 16, 2021, 08:00 ET Bantam plans to submit its Investigational New […]
Bantam Pharmaceutical Appoints Industry Veteran Michael Stocum as President and Chief Executive Officer New York, N.Y. - April 27, 2021 —Bantam Pharmaceutical, a drug discovery, and development company targeting selective modulation of mitochondrial dynamics in cancer, announced today that it has named Michael Stocum, MS as President and Chief Executive Officer. Mr. Stocum succeeds the […]